Presenter Profiles
-
Translational Research Controversies – Presenter Profile
Per Hall, MD, PhD, discusses a Friday afternoon presentation on the KARISMA-2 low dose tamoxifen trial.
-
Poster Spotlight Session 16: Enhancing Immunotherapy for Triple Negative Breast Cancer: Novel therapies and Biomarkers – Presenter Profile
Hans-Christian Kolberg, MD, PhD, discusses a Friday morning poster presentation analyzing the neoadjuvant neoMono trial.
-
Poster Spotlight Session 17: Biomarkers of Response and/or Resistance to Endocrine Based Therapies: Implications for Treatment Approaches – Presenter Profiles
Sacha Howell, PhD, FRCP, and Angel Guerrero-Zotano, MD, PhD, discuss their Friday morning poster presentations.
-
Poster Spotlight Session 18: Disparate Care Calls for Desperate Measures: Understanding Gaps in Quality of Care and Opportunities to Improve it – Presenter Profiles
Malcolm Bevel, PhD, MSPH; Richard J. Bleicher, MD, FACS; and Marcela Mazo-Canola, MD, discuss their Friday morning poster presentations.
-
Inflammatory Breast Cancer: Clinical Challenges, Evolving Concepts and Novel Treatments (People’s Choice) – Presenter Profile
Frederick Howard, MD, discusses a Thursday afternoon presentation on whether inflammatory breast cancer is a genomically different type of breast cancer.
-
Poster Spotlight Session 13: Special Populations: Pregnancy, Male and Geriatric Patients – Presenter Profile
Carsten F.J. Bakhuis discusses a Thursday evening poster presentation on worse prognosis for breast cancer in the second and third trimesters of pregnancy and shortly postpartum.
-
Poster Spotlight Session 14: Setting Expectations for Toxicities Related to I/O Therapy – Presenter Profile
Neelima Vidula, MD, discusses a Thursday evening poster presentation on immune related adverse events in patients over 65 years of age vs. those younger than 65 years with breast cancer who were treated with immunotherapy.
-
Poster Spotlight Session 15: Novel Nuclear Receptor Targeting Therapies – Presenter Profile
Erika Hamilton, MD, discusses a Thursday evening poster presentation on the activity of ARV-471 in combination with a CDK4/6 inhibitor in patients with HR+ metastatic breast cancer.
-
Poster Spotlight Session 10: Refining Prediction of Cancer Risk and Outcomes – Presenter Profiles
Mikael Eriksson, PhD, and Kelly-Anne Phillips, MBBS, MD, FRACP, discuss their Thursday morning poster presentations.
-
Poster Spotlight Session 12: Putting Brakes on the Cell Cycle: Understanding Mechanisms Governing CDK 4/6 inhibitor Resistance and Role for Novel Therapeutic Strategies – Presenter Profile
Barbara Pistilli, MD, discusses a Thursday morning poster presentation analyzing the CAPItello-292 Phase 1b trial.